Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Futura Medical ( (GB:FUM) ) has provided an update.
Futura Medical has received a notice of allowance for its patent for Eroxon® in China, providing protection until 2040. This development represents a significant commercial opportunity given the high prevalence of erectile dysfunction among adult males in China. The patent enhances Futura’s competitive position and supports its commercial strategy as the company seeks partners in the Chinese market. The allowance adds to Futura’s existing intellectual property protection in Europe, Hong Kong, Taiwan, and the US, with further applications pending in additional markets.
The most recent analyst rating on (GB:FUM) stock is a Buy with a £140.00 price target. To see the full list of analyst forecasts on Futura Medical stock, see the GB:FUM Stock Forecast page.
More about Futura Medical
Futura Medical plc is a consumer healthcare group specializing in the development and global commercialization of innovative and clinically proven sexual health products. The company’s core strength lies in its research, development, and commercialization of topically delivered gel formulations for sexual health issues. Its lead product, Eroxon®, is a topical gel treatment for erectile dysfunction (ED) available over the counter, addressing significant unmet needs in the ED market. Futura also has development products like WSD4000, a topical treatment for symptoms of impaired sexual response and function in women.
Average Trading Volume: 4,618,166
Technical Sentiment Signal: Sell
Current Market Cap: £6.77M
For a thorough assessment of FUM stock, go to TipRanks’ Stock Analysis page.